Clinical Trial Update: A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease [Phase 2]

View source ↗

Summary

Phase II pharmacokinetic/pharmacodynamic dose-ranging study of ticagrelor in pediatric patients with sickle cell disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• TICAGRELOR (ticagrelor)

Snippet

Sponsor: AstraZeneca | Conditions: Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-05-11